Stockscreener 앱 받기
2.545
2.12%
-0.055
전일 마감가:
$2.60
열려 있는:
$2.67
하루 거래량:
227.46K
Relative Volume:
0.16
시가총액:
$347.09M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-7.2714
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
-2.86%
1개월 성능:
+21.19%
6개월 성능:
+75.52%
1년 성능:
+169.17%
1일 변동 폭
$2.50
$2.67
1주일 범위
$2.50
$2.76
52주 변동 폭
$0.765
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
2.545 | 347.09M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.79 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.31 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
558.74 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech - The Globe and Mail
SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Bank of America Corp DE - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Sells 48,021 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Confirms Directors at Annual Meeting - TipRanks
Cholangiocarcinoma Market Booming Worldwide, Estimated to Reach USD 2,334.4 Mn by 2032 | Incyte CorporationSOUTHEAST - SOUTHEAST - NEWS CHANNEL NEBRASKA
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Squarepoint Ops LLC Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | - GuruFocus
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | CMPX Stock News - GuruFocus
Two Sigma Advisers LP Cuts Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Transition Metals (CVE:XTM) Shares Up 62.5% – Time to Buy? - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
BNP Paribas Financial Markets Makes New $27,000 Investment in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
ProShare Advisors LLC Has $42,000 Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Northern Trust Corp Sells 43,164 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (CMPX) Stock Analysis: A Biotech Gem with Over 500% Potential Upside - DirectorsTalk Interviews
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Insider Buying: Thomas Schuetz Acquires Additional Shares of Com - GuruFocus
Compass Therapeutics CEO acquires $21,100 in common stock - Investing.com Australia
Compass Therapeutics CEO acquires $21,100 in common stock By Investing.com - Investing.com India
Compass Therapeutics CEO Acquires 10,000 Shares - TradingView
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of “Buy” from Brokerages - Defense World
Dimensional Fund Advisors LP Buys New Stake in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World
Bell Investment Advisors Inc Buys 79 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Dark Forest Capital Management LP Cuts Stock Holdings in NVIDIA Co. (NASDAQ:NVDA) - Defense World
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Bought by Price T Rowe Associates Inc. MD - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Price T Rowe Associates Inc. MD - Defense World
Ceera Investments LLC Grows Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Apple Inc. (NASDAQ:AAPL) is Sound View Wealth Advisors Group LLC’s Largest Position - Defense World
Frontier Asset Management LLC Acquires 1,041 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
Rebalance LLC Grows Stake in Apple Inc. (NASDAQ:AAPL) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Voya Investment Management LLC Sells 5,102 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Spotlight On Three Promising Penny Stocks In May 2025 - Yahoo Finance
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Wells Fargo & Company MN Acquires 13,038 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers - Seeking Alpha
Guggenheim Cuts Compass Therapeutics (NASDAQ:CMPX) Price Target to $10.00 - Defense World
Barclays PLC Has $279,000 Stock Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Mariner LLC Purchases New Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Guggenheim Adjusts Price Target for Compass Therapeutics (CMPX) - GuruFocus
Compass Therapeutics (CMPX) Price Target Lowered by Guggenheim | CMPX Stock News - GuruFocus
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Compass Therapeutics Reports Q1 2025 Financial Results - TipRanks
Compass Therapeutics, Inc. SEC 10-Q Report - TradingView
Compass Therapeutics to Participate in Upcoming May Investor Events - GlobeNewswire
Renaissance Technologies LLC Grows Stock Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Compass Therapeutics Inc 주식 (CMPX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
1.21%
2.91%
자본화:
|
볼륨(24시간):